Chat with us
Research Assistance
Online
  • Please enter your first name.

China Gastrointestinal Therapeutics Market, 2025-2033

The gastrointestinal therapeutics market in China is expected to reach a projected revenue of US$ 4,394.9 million by 2033. A compound annual growth rate of 5.3% is expected of China gastrointestinal therapeutics market from 2026 to 2033.

  • Pharmaceuticals
    • GI therapeutics
      • gastrointestinal therapeutics market
Revenue, 2025 (US$M)
$2,905.7
Forecast, 2033 (US$M)
$4,394.9
CAGR, 2026 - 2033
5.3%
Report Coverage
China
China Gastrointestinal Therapeutics Market, 2021-2033 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Global Market

Related Markets

Prism AI by Grand View ResearchFree to try

Ask a question about the gastrointestinal therapeutics market

Every figure cited from GVR research

China gastrointestinal therapeutics market highlights

  • The China gastrointestinal therapeutics market generated a revenue of USD 2,905.7 million in 2025 and is expected to reach USD 4,394.9 million by 2033.
  • The China market is expected to grow at a CAGR of 5.3% from 2026 to 2033.
  • In terms of segment, branded was the largest revenue generating drug type in 2025.
  • Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.


Gastrointestinal therapeutics market data book summary

Market revenue in 2025USD 2,905.7 million
Market revenue in 2033USD 4,394.9 million
Growth rate5.3% (CAGR from 2026 to 2033)
Largest segmentBranded
Fastest growing segmentGenerics
Historical data2021 - 2024
Base year2025
Forecast period2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationBranded, Generics
Key market players worldwideAbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares


Other key industry trends

  • In terms of revenue, China accounted for 6.8% of the global gastrointestinal therapeutics market in 2025.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China gastrointestinal therapeutics market is projected to lead the regional market in terms of revenue in 2033.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 4,394.9 million by 2033.

China is anticipated to witness substantial market growth in the near future owing to rise in the prevalence of gastrointestinal diseases due to various socioeconomic factors, increase in R&D activities, and growing investments in healthcare industry.

In addition, increase in product approvals is also expected to fuel the market growth in the country. For instance, in January 2019, Ironwood Pharmaceuticals announced that its drug Linzess received approval from the National Medical Products Administration for the treatment of IBS in adults.

The drug was jointly developed by Ironwood and AstraZeneca, with the latter being responsible for commercialization of the drug in the country. Thus, rise in regulatory approvals of drugs can lead to rise in the options for the treatment of various IBS-related symptoms.

No credit card required*

Publish Date: Mar 20, 2026

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Gastrointestinal Therapeutics Market Companies

NameProfile# EmployeesHQWebsite
Abbott LaboratoriesView profile 114,000100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400www.abbottinvestor.com
AbbVie IncView profile 50,0001 North Waukegan Road, North Chicago, IL, United States, 60064-6400www.abbvieinvestor.com
Pfizer IncView profile 88,00066 Hudson Boulevard East, New York, NY, United States, 10001-2192www.pfizer.com
Cipla Ltd DRView profile 38,955Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013www.cipla.com
Bayer AGView profile 99,723Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368www.bayer.com
Sun Pharmaceutical IndustriesView profile 10001+Mumbai, Maharashtra, India, Asiawww.sunpharma.com
AstraZeneca PLCView profile 89,9001 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AAwww.astrazeneca.com
Gilead Sciences IncView profile 18,000333 Lakeside Drive, Foster, CA, United States, 94404www.gilead.com
Biogen IncView profile 7,570225 Binney Street, Cambridge, MA, United States, 02142www.biogen.com
Takeda Pharmaceutical Co LtdView profile 49,0951-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668www.takeda.com

China gastrointestinal therapeutics market

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gastrointestinal Therapeutics Market will help companies and investors design strategic landscapes.


Branded was the largest segment with a revenue share of 61.19% in 2025.

Horizon Databook has segmented the China gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2021 to 2033.




China is anticipated to witness substantial market growth in the near future owing to rise in the prevalence of gastrointestinal diseases due to various socioeconomic factors, increase in R&D activities, and growing investments in healthcare industry.

In addition, increase in product approvals is also expected to fuel the market growth in the country. For instance, in January 2019, Ironwood Pharmaceuticals announced that its drug Linzess received approval from the National Medical Products Administration for the treatment of IBS in adults.

The drug was jointly developed by Ironwood and AstraZeneca, with the latter being responsible for commercialization of the drug in the country. Thus, rise in regulatory approvals of drugs can lead to rise in the options for the treatment of various IBS-related symptoms.

  • China Gastrointestinal Therapeutics Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
    • Branded
    • Generics
  • China Gastrointestinal Therapeutics Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
    • Aminosalicylates
    • Digestive Enzymes
    • Proton Pump Inhibitors
    • Laxatives
    • Anti-emetics
    • H2 Antagonists
    • Anti-diarrheals
    • Biologics/Biosimilar
    • Other Drug Classes
  • China Gastrointestinal Therapeutics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
    • Oral
    • Injectables
    • Others Route of Administrations
  • China Gastrointestinal Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2033)
    • Crohn's disease
    • Ulcerative colitis
    • GERD
    • IBS
    • Others Applications
  • China Gastrointestinal Therapeutics Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Reasons to subscribe to gastrointestinal therapeutics market databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of gastrointestinal therapeutics market databook

  • Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into China gastrointestinal therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

China Gastrointestinal Therapeutics Market, 2021-2033 (US$M)

No Access Stack Chart

China gastrointestinal therapeutics market statistics, by drug type, 2021-2033 (US$M)

No Access Pie Chart

China gastrointestinal therapeutics market statistics, by drug type, 2021-2033 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more